I think one issue may be that Shire is more focused on the Baxalta deal and their later stage programs that will generate them money in the near future. In one of the presentations I recall seeing a director say that they were looking to prioritize their programs. They can still conduct normal operations with their other programs, but the final green light to proceed may be forced to wait. Good thing about dealing with major pharma is the deep pockets. Bad thing is doing things on their schedule.
Market Data 
Markets 
AI
